Sino Biopharmaceutical (OTCMKTS:SBMFF) Shares Gap Up - Still a Buy?

Key Points

• Sino Biopharmaceutical shares saw a significant increase, gapping up from a previous close of $0.99 to an opening price of $1.16.
• The company's 50-day and 200-day moving average prices are $0.90 and $0.64, respectively, indicating improving stock performance.
• Sino Biopharmaceutical is involved in research and development, offering various oncology, liver disease, and respiratory medicines in China.

Sino Biopharmaceutical (OTCMKTS:SBMFF - )'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $0.99, but opened at $1.16. Sino Biopharmaceutical shares last traded at $1.16, with a volume of 100 shares changing hands.

Sino Biopharmaceutical Price Performance

The firm's fifty day moving average price is $0.90 and its 200 day moving average price is $0.64.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.